Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 29

1.

Vector choice determines immunogenicity and potency of genetic vaccines against Angola Marburg virus in nonhuman primates.

Geisbert TW, Bailey M, Geisbert JB, Asiedu C, Roederer M, Grazia-Pau M, Custers J, Jahrling P, Goudsmit J, Koup R, Sullivan NJ.

J Virol. 2010 Oct;84(19):10386-94. doi: 10.1128/JVI.00594-10. Epub 2010 Jul 21.

2.

[Novel vaccines against M. tuberculosis].

Okada M.

Kekkaku. 2006 Dec;81(12):745-51. Review. Japanese.

PMID:
17240920
3.

Progress in DNA-based heterologous prime-boost immunization strategies for malaria.

Moore AC, Hill AV.

Immunol Rev. 2004 Jun;199:126-43. Review.

PMID:
15233731
4.
5.

Progress in filovirus vaccine development: evaluating the potential for clinical use.

Falzarano D, Geisbert TW, Feldmann H.

Expert Rev Vaccines. 2011 Jan;10(1):63-77. doi: 10.1586/erv.10.152. Review.

6.

Progress in recombinant DNA-derived vaccines for Lassa virus and filoviruses.

Grant-Klein RJ, Altamura LA, Schmaljohn CS.

Virus Res. 2011 Dec;162(1-2):148-61. doi: 10.1016/j.virusres.2011.09.005. Epub 2011 Sep 10. Review.

PMID:
21925552
7.

Recombinant vesicular stomatitis virus-based vaccines against Ebola and Marburg virus infections.

Geisbert TW, Feldmann H.

J Infect Dis. 2011 Nov;204 Suppl 3:S1075-81. doi: 10.1093/infdis/jir349. Review.

8.

Utilizing poxviral vectored vaccines for antibody induction-progress and prospects.

Draper SJ, Cottingham MG, Gilbert SC.

Vaccine. 2013 Sep 6;31(39):4223-30. doi: 10.1016/j.vaccine.2013.05.091. Epub 2013 Jun 5. Review.

PMID:
23746455
9.

Protective role of cytotoxic T lymphocytes in filovirus hemorrhagic fever.

Warfield KL, Olinger GG.

J Biomed Biotechnol. 2011;2011:984241. doi: 10.1155/2011/984241. Epub 2011 Dec 28. Review.

10.

The prime-boost strategy: exciting prospects for improved vaccination.

Ramshaw IA, Ramsay AJ.

Immunol Today. 2000 Apr;21(4):163-5. Review. No abstract available.

PMID:
10740236
11.

[DNA vaccine].

Nishikawa H, Shiku H.

Nihon Rinsho. 2008 Oct;66(10):1867-72. Review. Japanese.

PMID:
18939483
12.

Advances in virus-like particle vaccines for filoviruses.

Warfield KL, Aman MJ.

J Infect Dis. 2011 Nov;204 Suppl 3:S1053-9. doi: 10.1093/infdis/jir346. Review.

13.

Recombinant viruses as vaccines against viral diseases.

Souza AP, Haut L, Reyes-Sandoval A, Pinto AR.

Braz J Med Biol Res. 2005 Apr;38(4):509-22. Epub 2005 Apr 13. Review.

14.

Viral vectors as vaccine platforms: from immunogenicity to impact.

Ewer KJ, Lambe T, Rollier CS, Spencer AJ, Hill AV, Dorrell L.

Curr Opin Immunol. 2016 Aug;41:47-54. doi: 10.1016/j.coi.2016.05.014. Epub 2016 Jun 7. Review.

PMID:
27286566
15.

DNA vaccines for viral diseases.

Donnelly JJ, Ulmer JB.

Braz J Med Biol Res. 1999 Feb;32(2):215-22. Review.

PMID:
10347757
16.

DNA-antiviral vaccines: new developments and approaches--a review.

Giese M.

Virus Genes. 1998;17(3):219-32. Review.

PMID:
9926398
17.

DNA vaccines: developing new strategies to enhance immune responses.

Abdulhaqq SA, Weiner DB.

Immunol Res. 2008;42(1-3):219-32. doi: 10.1007/s12026-008-8076-3. Review.

PMID:
19066740
18.

Replicating and non-replicating viral vectors for vaccine development.

Robert-Guroff M.

Curr Opin Biotechnol. 2007 Dec;18(6):546-56. Epub 2007 Dec 11. Review.

19.

Viral vectors as vaccine platforms: deployment in sight.

Rollier CS, Reyes-Sandoval A, Cottingham MG, Ewer K, Hill AV.

Curr Opin Immunol. 2011 Jun;23(3):377-82. doi: 10.1016/j.coi.2011.03.006. Epub 2011 Apr 20. Review.

PMID:
21514130
20.

Improving DNA vaccines targeting viral infection.

Sin JI, Weiner DB.

Intervirology. 2000;43(4-6):233-46. Review.

PMID:
11251379

Supplemental Content

Support Center